India: Delhi High Court Strikes Down Notification Dated 10 March 2016 Issued By The Government Of India Banning 344 Fixed Dose Combination (FDC) Drugs

A single judge of the Delhi High Court, Justice Rajiv Sahai Endlaw vide his Order and Judgment dated 1 December 2016 has struck down the notification dated 10 March, 2016 issued by the Central Government, through its Department of Health & Family Welfare ("Notification"); whereby 344 Fixed Dose Combination (FDC) Drugs were banned with immediate effect. This came as a rude shock to hundreds of pharmaceutical companies.


FDCs are combinations of two or more active pharmaceutical ingredients in fixed ratios, given in the form of a single dose. Widely popular Indian drugs, such as Pfizer's Corex, D'Cold Total, Piramal Healthcare's Saridon, Merck India's Nasivion, Glenmark's Ascoril and Candibiotic, Lupin's Gluconorm amongst many others fell under the list of the banned FDCs. Needless to say, the Notification adversely affected almost the entire Indian pharmaceutical industry; and had the Notification gone unchallenged – the industry was set to lose revenue amounting to approximately INR 3,000 Crores, annually.

The Notification purported to ban the FDCs in question because they involved risks to human beings and safer alternatives were available. The Notification was also purported to be based on the findings and recommendations of an Expert Committee appointed by the Central Government, which stated that the FDCs in question were found to have no 'therapeutic justification'. Lastly, the Notification was touted as an exercise in 'public interest'.

It may be relevant to note that the Notification was issued under Section 26A of the Drugs & Cosmetics Act, 1940 ("the Act") which reads as under -

"26A. Power of Central Government to prohibit manufacture, etc., of drug and cosmetic in public interest.— Without prejudice to any other provision contained in this Chapter, if the Central Government is satisfied, that the use of any drug or cosmetic is likely to involve any risk to human beings or animals or that any drug does not have the therapeutic value claimed or purported to be claimed for it or contains ingredients and in such quantity for which there is no therapeutic justification and that in the public interest it is necessary or expedient so to do, then, that Government may, by notification in the Official Gazette, prohibit the manufacture, sale or distribution of such drug or cosmetic."


The pharmaceutical industry immediately proceeded to challenge the Notification on various grounds. Although several writ petitions were filed before various High Courts of the country, the Delhi High Court, having passed the first order concerning the Notification in WP(C) No. 2212 of 2016 filed by M/s Pfizer Ltd., became the most controversial. Accordingly, a total of 455 writ petitions came to be filed before the Delhi High Court by various companies and were heard by Justice Endlaw, over a period of nearly three months, with several days of back to back hearings.

The broad grounds of challenge were as follows:

  • Violation of Article 14 of the Constitution of India, in as much as the Notification was issued in an arbitrary manner; in violation of the principles of natural justice; was unreasonable, harsh and unscientific.
  • Violation of Article 19(1)g of the Constitution of India, in as much as the Notification was an unreasonable restriction upon the business and trade of the Petitioners.
  • Violation of the procedure prescribed under the Act, for exercise of powers under Section 26A, in as much as the Notification was issued without the mandatory consultation with the Drugs Technical Advisory Board ("DTAB") and the Drugs Consultative Committee ("DCC"), as constituted pursuant to Sections 5 and 7 of the Act, respectively.

The primary ground of challenge in most of the petitions was that there was a violation of the principles of natural justice, more specifically the principle of audi alteram partem – in as much as no show-cause notice was issued to the Petitioners, enabling them to empirically justify their production/ sale of the banned FDCs. It may be noted that a show-cause notice had been duly issued to some of the petitioners; and the said petitioners, nonetheless, went on to challenge the Notification, inter alia, on the ground that no personal hearing was afforded to them.

It was also stated that most of the affected drugs had been in production for several years (decades, in some cases); and had been successful in treating lakhs of patients across the country. Accordingly, it was submitted that the ban was unwarranted and its imposition with immediate effect was especially arbitrary and unreasonable.

More importantly, the Hon'ble Court was apprised of the fact that the FDCs in question, in most of the petitions, had been under production pursuant to requisite licenses and approvals that had been duly issued by the Drugs Controller General of India DCG (I) and/ or the relevant State Authorities. In this regard, it was submitted that the said licenses and approvals were given only after examining the efficacy and suitability of the relevant drug; and that it was astonishing that the Government, would now brand the same drugs as unsafe in a sudden and arbitrary manner.

Apart from the above, certain other grounds of challenge included (i) alleged violation of the procedure adopted; (ii) perverse constitution of the Expert Committee; (iii) unscientific methods adopted to reach the conclusion that the FDCs in question did not have any therapeutic justification etc.

Ever since the institution of the first petition, the proceedings, which were nothing short of a marathon, went on for a period of almost three months, before the Hon'ble Court was pleased to finally reserve the matters for Judgment on 2 June 2016. Several highly regarded senior counsel in the Country represented the various companies.


The Hon'ble Court was pleased to allow the writ petitions and quash the Notification. The pharmaceutical industry may well be advised to adopt a 'wait and watch' approach for the fallout of the judgement and the Governments' future of action.


As already stated, the impugned Notification threatened the pharmaceutical industry of the country, with a loss of approximately INR. 3,000 Crores, annually; and thus, the proceedings before the Hon'ble Delhi High Court were one of the largest corporate battles to have ever been undertaken.

The proceedings also assume importance as the impugned action of the Central Government was purportedly undertaken to further public interest, particularly the protection of public health. In such circumstances, the Hon'ble Court was faced with a fairly vexed issue and was called upon to circumscribe the powers of the Central Government, within the contours of the procedure prescribed under the specific law and the settled principles of common law. To that end, the Hon'ble Court made it clear that an exercise affecting substantive rights, if undertaken in violation of the law, would not be permitted to prevail, notwithstanding the fact that it is seemingly peddled to be in furtherance of public interest.

It will now be interesting to see how the Central Government reacts to the decision of the Hon'ble Delhi High Court. The following three possibilities, in no order of likelihood, seem to be in the offing:

  • The Central Government may accept the decision and give up the entire exercise concerning FDC Drugs, altogether.
  • It may accept the decision, but, go on to undertake the entire exercise afresh removing the infirmities, as pointed out before the Hon'ble Delhi High Court.
  • It may challenge the decision and file an appeal against the same.

Khaitan & Co, New Delhi acted for several of the affected Pharmaceutical Companies, namely, Glenmark Pharmaceuticals Ltd., GlaxoSmithKline Pharmaceuticals Ltd., Lupin Ltd., Wockhardt Ltd., Unichem Laboratories Ltd., Ajanta Pharma Ltd., Centaur Pharmaceuticals Pvt. Ltd. Blue Cross Laboratories Ltd., Tablet India Ltd., Unichem labs Pvt. Ltd., Yash Pharma Ltd., Serum Institute Ltd., FDC India Ltd., Coral Laboratories Ltd., Ruby Organic & Labs Ltd., Akums Drug and Pharma Ltd., Koye Pharmaceutical  Ltd., Hema Laboratories  Ltd. amongst others; and filed over 50 writ petitions

The content of this document do not necessarily reflect the views/position of Khaitan & Co but remain solely those of the author(s). For any further queries or follow up please contact Khaitan & Co at

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions